{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:56Z","timestamp":1793666756478,"version":"4.5.1"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,4,20]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies. Serum levels of acute phase reactants C reactive protein (CRP) and serum amyloid A (SAA) and inflammatory cytokines\/chemokines were measured at weeks 0, 4 and 24 in 300 study participants and 34 healthy controls (HCs). The PSUMMIT studies measured serum interleukin (IL)-17A, IL-17F and CRP after ustekinumab treatment and levels with ustekinumab versus guselkumab treatment were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline serum levels of CRP, SAA, IL-6, IL-17A and IL-17F were elevated in participants with active PsA vs HCs (p&lt;0.05, geometric mean (GM) \u226540% higher). Baseline T-helper cell 17 (Th17) effector cytokines were significantly associated with baseline psoriasis but not joint disease activity. Compared with placebo, guselkumab treatment resulted in decreases in serum CRP, SAA, IL-6, IL-17A, IL-17F and IL-22 as early as week 4 and continued to decrease through week 24 (p&lt;0.05, GM decrease from baseline \u226533%). At week 24, IL-17A and IL-17F levels were not significantly different from HCs, suggesting normalisation of peripheral IL-23\/Th17 axis effector cytokines postguselkumab treatment. Reductions in IL-17A\/IL-17F levels were greater in guselkumab-treated versus ustekinumab-treated participants, whereas effects on CRP levels were similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Guselkumab treatment reduced serum protein levels of acute phase and Th17 effector cytokines and achieved comparable levels to those in HCs. In participants with PsA, reductions of IL-17A and IL-17F were of greater magnitude after treatment with guselkumab than with ustekinumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001679","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:36:24Z","timestamp":1621431384000},"page":"e001679","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct03162796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158285","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-003X","authenticated-orcid":false,"given":"Kristen","family":"Sweet","sequence":"first","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxuan","family":"Song","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Loza","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keying","family":"Ma","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Leander","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Lakshminarayanan","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Franks","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cooper","sequence":"additional","affiliation":[{"name":"Immunology Therapeutic Area, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"2025090312324662000_7.2.e001679.1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090312324662000_7.2.e001679.2","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/art.40921","article-title":"Responsiveness of serum C-reactive protein, interleukin-17A, and Interleukin-17F levels to ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials","volume":"71","author":"Siebert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312324662000_7.2.e001679.3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090312324662000_7.2.e001679.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213654"},{"key":"2025090312324662000_7.2.e001679.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2025090312324662000_7.2.e001679.6","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2025090312324662000_7.2.e001679.7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312324662000_7.2.e001679.8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2025090312324662000_7.2.e001679.9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2025090312324662000_7.2.e001679.10","unstructured":"U.S. Food and Drug Administration . Part 630\u2014Requirements For Blood and Blood Components Intended For Transfusion Or For Further Manufacturing Use [Internet]. Electronic Code of Federal Regulations, 2020."},{"key":"2025090312324662000_7.2.e001679.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2025090312324662000_7.2.e001679.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025090312324662000_7.2.e001679.13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjd.18634","article-title":"Adjusted treatment comparisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis","volume":"183","author":"Diels","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090312324662000_7.2.e001679.14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030896"},{"key":"2025090312324662000_7.2.e001679.15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/rheumatology\/kex186","article-title":"The role of IL-12\/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade","volume":"57","author":"Schurich","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312324662000_7.2.e001679.16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjd.19380","article-title":"Role of regulatory T cells in psoriasis pathogenesis and treatment","volume":"184","author":"Nussbaum","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025090312324662000_7.2.e001679.17","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","author":"Nerviani","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312324662000_7.2.e001679.18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312324662000_7.2.e001679.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:32:53Z","timestamp":1756927973000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/rmdopen-2021-001679"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001679","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}